Structure-based drug design: Opening the door to an epigenetic target

Nature Reviews Drug Discovery

Volumn 11, Issue 9, 2012, Pages 672-673

  Harrison, Charlotte ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; GSK J 1; GSK J 4; HISTONE; HISTONE DEMETHYLASE; JMJD3 DEMETHYLASE; LIPOPOLYSACCHARIDE; LYSINE; METAL ION; RNA POLYMERASE II; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UTX DEMETHYLASE;

BINDING KINETICS; CATION TRANSPORT; COMPLEX FORMATION; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DEMETHYLATION; DRUG BINDING; DRUG DESIGN; DRUG PENETRATION; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; EPIGENETICS; HUMAN; HYDROGEN BOND; MACROPHAGE; MOLECULAR RECOGNITION; NOTE; PRIORITY JOURNAL; PROTEIN DOMAIN; RHEUMATOID ARTHRITIS;

EID: 84866070181     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3827     Document Type: Note

References (2)

1. ORIGINAL RESEARCH PAPER Kruidenier, L. et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488, 404-408 (2012)
2. FURTHER READING Arrowsmith, C. H. et al. Epigenetic protein families: a new frontier for drug discovery. Nature Rev. Drug Discov. 11, 384-400 (2012)